10-Apr-17 DoctorOnCall debuts as Malaysia’s first online telehealth platform that connects patients with an extensive network of doctors and medical practitioners via audio or video call. DoctorOnCall.com.my has also become Malaysia’s first online prescription-based pharmacy, with average delivery times of 4-6 hours for areas within Kuala Lumpur and the Klang Valley, and 1-2 days for the rest of Malaysia. [image: Citizen Journalists Malaysia]

06-Apr-17 In Japanese companies' largest study to date, Takeda will test an experimental dengue vaccine on 20,100 children and adolescents in eight countries in Latin America. Takeda said it has completed enrollment for a 20,000-subject dengue vaccine trial, the largest clinical study in its history, signalling the global ambitions of its vaccine business. [image: ET Healthworld]

05-Apr-17 Singapore based Zuellig Pharma has launched Zuellig Health Solutions innovation centre, in Singapore and plans to invest over USD35 mn in the next five years. On why it chose Singapore for its new venture, CEO John Davison said: "We see many of our clients in the pharmaceutical and consumer health sector (such as) GlaxoSmithKline and AstraZeneca here in Singapore." [image: Zuellig Pharma]

27-Mar-17 Ericsson has partnered with China Mobile and AstraZeneca to connect healthcare equipment using NB-IoT technology. China Mobile’s Jiangsu branch and Ericsson will work together to trial new applications using cellular IoT technologies like NB-IoT and provide network terminal management to support equipment management. Additionally, AstraZeneca is also working with the Wuxi government to open a China Commercial Innovation Center. [image: Wireless Week / Ericsson].

31-Mar-17 Without much press or international recognition, Chinese companies have been making good progress enhancing their pharmaceutical and healthcare prowess. For example, in the past few years, 50+ Chinese pharmaceutical companies have entered or completed phase I and phase II clinical trials, while 10+ companies have completed phase III trials. [image: China Money Network